Back to results
US 2004/0071633 A1Published application
Method for determining efficacy of reverse cholesterol transport enhancing agents
OwnerSamuel D. Wright, Tian-Quan Caiinventors
Life of this patent
Estimating the term…
Abstract
This invention provides a method for screening and/or determining the efficacy of known or potential reverse cholesterol transport-enhancing compounds in mammals that avoids the need for measuring cellular protein or mRNA levels and instead employs measurements of CD14 levels in blood.
Claims20
A method for evaluating the efficacy of a reverse cholesterol transport-enhancing test agent in a mammal comprising
- measuring the level of CD14 protein present in a standard sample of the mammal's blood to obtain one CD14 protein measurement;
- measuring the level of CD14 protein present in a sample of the mammal's blood after administration of the test agent to obtain a second CD14 protein measurement;
- and
- comparing the two CD14 protein measurements to determine if the measurement obtained after test agent administration is greater than the measurement obtained from the standard blood sample;
- and wherein the CD14 protein is selected from sCD14 and mCD14 and is the same for both measurements.
2 more elements
A method for determining relative efficacy for a reverse cholesterol transport-enhancing test agent in a mammal comprising:
- measuring the level of CD14 protein present in a sample of the mammal's blood after administration of a standard RCT-enhancing agent to obtain one CD14 protein measurement;
- measuring the level of CD14 protein present in a sample of the mammal's blood after administration of the test agent to obtain a second CD14 protein measurement;
- and
- comparing the two CD14 protein measurements to determine the relative efficacy of the test agent as compared to that of the standard RCT-enhancing agent;
- and wherein the CD14 protein is selected from sCD14 and mCD14 and is the same for both measurements.
2 more elements
Dependencies are inferred from the claim text.